Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

39.18 +0.35 (+0.89%)
Streaming Delayed Price Updated: 12:58 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enliven Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 ↗
ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
7 A-Rated Biotech Stocks for Your August Buy List ↗
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
Via InvestorPlace
News headline image
Bears Reload On Mobileye After Sharp Gains In Stock Price ↗
Short interest on Mobileye Global fell from 23.9% to 21.2% in the week following the company’s Q1 results and FY23 guidance cut on April 27. However, Mobileye shares are up 31% from those lows over the... 
Via Talk Markets
News headline image
7 Biotech Stocks Sitting in the Sweet Spot ↗
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023 ↗
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.